Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication

Clinical Chemistry

Volumn 44, Issue 5, 1998, Pages 914-917

  Steijns, Linda S W ^a   Van Der Weide, Jan ^a  

^a Psychiatric Hospital Veldwijk   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE;

ADULT; ALLELE; ARTICLE; CAUCASIAN; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE DUPLICATION; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 0031923119     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.5.914     Document Type: Article

References (25)

1. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36: 537-47.
2. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993; 3:61-70.
3. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
4. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
5. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphism of debrisoquine and mephenytoin in European population. Eur J Clin Pharmacol 1990;39:533-7.
6. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990;265: 17209-14.
7. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M. Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990;347:773-5.
8. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991;48:943-50.
9. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994;3:923-6.
10. Evert B, Griese EU, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schmiedeberg's Arch Pharmacol 1994;350: 434-9.
11. Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Broly F, A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995;5:305-11.
12. Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Boone P, Broly F. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Hum Genet 1996;97:668-70.
13. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996;6:319-28.
14. Chen S, Wen-Hwei C, Blouin RA, Mao Z, Humphries LL, Craig Meek Q, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-34.
15. Dahl ML, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992;51:12-7.
16. Bertilsson L, Dahl ML, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993;341:63.
17. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90: 11825-9.
18. Agúndez JAG, Ledesma MC, Ladero JM, Benítez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57: 265-9.
19. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.
20. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996;6:351-5.
21. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996;392:30-4.
22. Wolf CR, Moss JE, Miles JS, Gough AC, Spurr NK. Detection of debrisoquine hydroxylation phenotypes. Lancet 1990;336: 1452-3.
23. Masimirembwa CW, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993;3:275-80.
24. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of Ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441-6.
25. Brockmöller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 1994;27:216-48.-